Coskun Meric
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Coskun Meric has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Alper Sonmez
Department of Endocrinology and Metabolism, Ankara Güven Hospital, Ankara, Turkey
19 shared publications Aydogan Aydogdu
Department of Endocrinology and Metabolism, Gulhane Training and Research Hospital - 06010, Etlik, Ankara, Turkey
15 shared publicationsOmer Azal
Department of Endocrinology and Metabolism, Gulhane Training and Research Hospital - 06010, Etlik, Ankara, Turkey
15 shared publications- Mustafa Dinc
Department of Endocrinology and Metabolism, Gulhane School of Medicine, 06018, Etlik, Ankara, Turkey
12 shared publications - Cem Haymana
Department of Endocrinology and Metabolism, University of Health Sciences, Gülhane Training and Research Hospital, Ankara, Turkey
11 shared publications Orhan Demir
Department of Endocrinology and Metabolism, Gulhane Faculty of Medicine and Gulhane Training and Research Hospital, University of Health Sciences 06018 Ankara, Turkey
10 shared publications
Latest Publications
- 1 January 2024
- Published by e-Century Publishing Corporation in American Journal of Translational Research
- Vol. 16 (11) , 6679-6688
Triglyceride-glucose index in patients with non-functioning adrenal incidentaloma, cortisol-secreting adrenal incidentaloma and healthy controls
Objective: Cushing’s syndrome increases the risk of cardiovascular disease. The triglyceride-glucose (TyG) index has been linked to an increased risk of cardiometabolic disorders. Whether patients with non-functioning adrenal incidentaloma (NFAI) or cortisol-secreting adrenal incidentaloma (CSAI) have altered TyG index is unknown. Therefore, we aimed to investigate the TyG index between adrenal incidentaloma patients and controls. Materials and methods: This cross-sectional study retrospectively included patients with NFAI, CSAI and healthy controls admitted to a tertiary endocrinology service. Subjects receiving hormone replacement, or having cancer, diabetes mellitus, alcoholism, psychiatric disorders, hepatic and/or renal insufficiency or morbid obesity were excluded. TyG index was calculated using the following formula: (Ln [fasting triglyceride (mg/dL) × fasting glucose (mg/dL)]/2). The primary endpoint was the difference in TyG index between patients with NFAI, CSAI and healthy controls. Results: A total of 142 patients with incidentaloma [NFAI, n=95, age: 60.9±10.6 years, women: 75.8%; CSAI, n=47, age: 59.6±13.7 years, women: 63.8%] and 116 age and sex matched healthy controls (age: 59.8±13.4 years, women: 76.7%) were evaluated. Compared with healthy controls, patients with overall incidentaloma, NFAI and CSAI had increased TyG index (6.39±1.87 vs. 8.85±0.52, 8.76±0.25, and 8.81±0.51, respectively, P<0.001 for all). There was no difference in TyG index between patients with NFAI and CSAI (8.76±0.25 vs. 8.81±0.51), and with possible autonomous cortisol secretion, autonomous cortisol secretion and Cushing’s syndrome (8.80±0.54, 8.86±0.52 and 9.31±0.37). Conclusion: This study showed increased TyG index in patients with NFAI or CSAI, emphasizing the importance of cardiometabolic risk assessment in patients with adrenal incidentaloma even if it is non-functioning.
- 1 January 2024
- Published by e-Century Publishing Corporation in American Journal of Translational Research
- Vol. 16 (11) , 6679-6688
Triglyceride-glucose index in patients with non-functioning adrenal incidentaloma, cortisol-secreting adrenal incidentaloma and healthy controls
Objective: Cushing’s syndrome increases the risk of cardiovascular disease. The triglyceride-glucose (TyG) index has been linked to an increased risk of cardiometabolic disorders. Whether patients with non-functioning adrenal incidentaloma (NFAI) or cortisol-secreting adrenal incidentaloma (CSAI) have altered TyG index is unknown. Therefore, we aimed to investigate the TyG index between adrenal incidentaloma patients and controls. Materials and methods: This cross-sectional study retrospectively included patients with NFAI, CSAI and healthy controls admitted to a tertiary endocrinology service. Subjects receiving hormone replacement, or having cancer, diabetes mellitus, alcoholism, psychiatric disorders, hepatic and/or renal insufficiency or morbid obesity were excluded. TyG index was calculated using the following formula: (Ln [fasting triglyceride (mg/dL) × fasting glucose (mg/dL)]/2). The primary endpoint was the difference in TyG index between patients with NFAI, CSAI and healthy controls. Results: A total of 142 patients with incidentaloma [NFAI, n=95, age: 60.9±10.6 years, women: 75.8%; CSAI, n=47, age: 59.6±13.7 years, women: 63.8%] and 116 age and sex matched healthy controls (age: 59.8±13.4 years, women: 76.7%) were evaluated. Compared with healthy controls, patients with overall incidentaloma, NFAI and CSAI had increased TyG index (6.39±1.87 vs. 8.85±0.52, 8.76±0.25, and 8.81±0.51, respectively, P<0.001 for all). There was no difference in TyG index between patients with NFAI and CSAI (8.76±0.25 vs. 8.81±0.51), and with possible autonomous cortisol secretion, autonomous cortisol secretion and Cushing’s syndrome (8.80±0.54, 8.86±0.52 and 9.31±0.37). Conclusion: This study showed increased TyG index in patients with NFAI or CSAI, emphasizing the importance of cardiometabolic risk assessment in patients with adrenal incidentaloma even if it is non-functioning.
- Open Access
- 3 February 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (3) , 378-384
Triglyceride-glucose index levels in patients with Klinefelter syndrome and its relationship with endothelial dysfunction and insulin resistance: a cross-sectional observational study
Objectives: This study aimed to investigate the triglyceride-glucose (TyG) index, which is a simple surrogate marker of insulin resistance that is associated with various cardiometabolic diseases, in patients with Klinefelter syndrome (KS). Subjects and methods: A total of 30 patients with KS (mean age: 21.53 ± 1.66 years) and 32 healthy controls (mean age: 22.07 ± 1.01 years) were included in the study.The clinical and laboratory parameters,TyG index, asymmetric dimethylarginine (ADMA) level, homeostatic model assessment of insulin resistance (HOMA-IR) [...] ABSTRACT Objectives: This study aimed to investigate the triglyceride-glucose (TyG) index, which is a simple surrogate marker of insulin resistance that is associated with various cardiometabolic diseases, in patients with Klinefelter syndrome (KS). Subjects and methods: A total of 30 patients with KS (mean age: 21.53 ± 1.66 years) and 32 healthy controls (mean age: 22.07 ± 1.01 years) were included in the study.The clinical and laboratory parameters,TyG index, asymmetric dimethylarginine (ADMA) level, homeostatic model assessment of insulin resistance (HOMA-IR)
- 3 February 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (3) , 378-384
Open AccessTriglyceride-glucose index levels in patients with Klinefelter syndrome and its relationship with endothelial dysfunction and insulin resistance: a cross-sectional observational study
Objectives: This study aimed to investigate the triglyceride-glucose (TyG) index, which is a simple surrogate marker of insulin resistance that is associated with various cardiometabolic diseases, in patients with Klinefelter syndrome (KS). Subjects and methods: A total of 30 patients with KS (mean age: 21.53 ± 1.66 years) and 32 healthy controls (mean age: 22.07 ± 1.01 years) were included in the study.The clinical and laboratory parameters,TyG index, asymmetric dimethylarginine (ADMA) level, homeostatic model assessment of insulin resistance (HOMA-IR) [...] ABSTRACT Objectives: This study aimed to investigate the triglyceride-glucose (TyG) index, which is a simple surrogate marker of insulin resistance that is associated with various cardiometabolic diseases, in patients with Klinefelter syndrome (KS). Subjects and methods: A total of 30 patients with KS (mean age: 21.53 ± 1.66 years) and 32 healthy controls (mean age: 22.07 ± 1.01 years) were included in the study.The clinical and laboratory parameters,TyG index, asymmetric dimethylarginine (ADMA) level, homeostatic model assessment of insulin resistance (HOMA-IR)
- Open Access
- 5 December 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (2) , 179-188
Evaluation of sexual functional status and consistency of scales in patients with hypogonadotropic hypogonadism before and after testosterone replacement therapy: a single-center experience
Objective: This study aimed to investigate the frequency of sexual dysfunction and the effect of short-term testosterone replacement therapy on sexual functions in congenital hypogonadism patients. Furthermore, we sought to reveal the consistency of the self-report scales used for the diagnosis of sexual dysfunction and the relationship between biochemical parameters. Materials and methods: The study was conducted on 47 young male patients aged above 18 years who were diagnosed with hypogonadotropic hypogonadism. Short (IIEF-5) and long (IIEF-15) forms of [...] ABSTRACT Objective: This study aimed to investigate the frequency of sexual dysfunction and the effect of short-term testosterone replacement therapy on sexual functions in congenital hypogonadism patients. Furthermore, we sought to reveal the consistency of the self-report scales used for the diagnosis of sexual dysfunction and the relationship between biochemical parameters. Materials and methods: The study was conducted on 47 young male patients aged above 18 years who were diagnosed with hypogonadotropic hypogonadism. Short (IIEF-5) and long (IIEF-15) forms of
- 5 December 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (2) , 179-188
Open AccessEvaluation of sexual functional status and consistency of scales in patients with hypogonadotropic hypogonadism before and after testosterone replacement therapy: a single-center experience
Objective: This study aimed to investigate the frequency of sexual dysfunction and the effect of short-term testosterone replacement therapy on sexual functions in congenital hypogonadism patients. Furthermore, we sought to reveal the consistency of the self-report scales used for the diagnosis of sexual dysfunction and the relationship between biochemical parameters. Materials and methods: The study was conducted on 47 young male patients aged above 18 years who were diagnosed with hypogonadotropic hypogonadism. Short (IIEF-5) and long (IIEF-15) forms of [...] ABSTRACT Objective: This study aimed to investigate the frequency of sexual dysfunction and the effect of short-term testosterone replacement therapy on sexual functions in congenital hypogonadism patients. Furthermore, we sought to reveal the consistency of the self-report scales used for the diagnosis of sexual dysfunction and the relationship between biochemical parameters. Materials and methods: The study was conducted on 47 young male patients aged above 18 years who were diagnosed with hypogonadotropic hypogonadism. Short (IIEF-5) and long (IIEF-15) forms of
- Open Access
- 1 September 2021
- Published by Galenos Yayinevi in Gulhane Medical Journal
- Vol. 63 (3) , 205-211
Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study
- 1 September 2021
- Published by Galenos Yayinevi in Gulhane Medical Journal
- Vol. 63 (3) , 205-211
Open AccessHematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study
- 12 June 2018
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 18 (4) , 401-406
Increased Endothelial Dysfunction and Insulin Resistance in Patients with Klinefelter Syndrome
Patients with Klinefelter Syndrome (KS) have increased cardiometabolic risk however the pathogenesis is not clear. We investigated the presence of endothelial dysfunction, insulin resistance and inflammation in an unconfounded population of KS. A total of 32 patients with KS (mean age 21.59 ± 1.66 years) and 33 healthy control subjects (mean age: 22.15 ± 1.03 years) were enrolled. The demographic parameters, Asymmetric dimethylarginine (ADMA), homeostatic model assessment of insulin resistance (HOMA–IR) index and high–sensitivity C–reactive protein (hs–CRP) levels were measured. The patients had higher Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH), insulin, HOMA–IR and ADMA levels (p < 0.001 for all) and lower High Density Lipoprotein Cholesterol (HDL–C) and total testosterone levels (p=0.002 and p<0.001, respectively), compared to the healthy controls. Total testosterone levels were significantly negatively correlated to ADMA (r = -0.479, p < 0,001), hs–CRP (r = -0.291, p = 0.034) and positively correlated to HDL–C (r = 0.429, p = 0.001) levels. The multivariate analysis has shown that total testosterone (β = -0.412, p = 0.001) and TG (β = 0.332, p = 0.009) levels were the significant independent determinants of the plasma ADMA levels. The results of the present study show that endothelial dysfunction and insulin resistance are prevalent even in the very young subjects with KS, who have no metabolic or cardiac problems at present. Also, hypogonadism seems to play an important role for increased cardiometabolic risk in patients with KS.
- 12 June 2018
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 18 (4) , 401-406
Increased Endothelial Dysfunction and Insulin Resistance in Patients with Klinefelter Syndrome
Patients with Klinefelter Syndrome (KS) have increased cardiometabolic risk however the pathogenesis is not clear. We investigated the presence of endothelial dysfunction, insulin resistance and inflammation in an unconfounded population of KS. A total of 32 patients with KS (mean age 21.59 ± 1.66 years) and 33 healthy control subjects (mean age: 22.15 ± 1.03 years) were enrolled. The demographic parameters, Asymmetric dimethylarginine (ADMA), homeostatic model assessment of insulin resistance (HOMA–IR) index and high–sensitivity C–reactive protein (hs–CRP) levels were measured. The patients had higher Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH), insulin, HOMA–IR and ADMA levels (p < 0.001 for all) and lower High Density Lipoprotein Cholesterol (HDL–C) and total testosterone levels (p=0.002 and p<0.001, respectively), compared to the healthy controls. Total testosterone levels were significantly negatively correlated to ADMA (r = -0.479, p < 0,001), hs–CRP (r = -0.291, p = 0.034) and positively correlated to HDL–C (r = 0.429, p = 0.001) levels. The multivariate analysis has shown that total testosterone (β = -0.412, p = 0.001) and TG (β = 0.332, p = 0.009) levels were the significant independent determinants of the plasma ADMA levels. The results of the present study show that endothelial dysfunction and insulin resistance are prevalent even in the very young subjects with KS, who have no metabolic or cardiac problems at present. Also, hypogonadism seems to play an important role for increased cardiometabolic risk in patients with KS.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Hematological indices in congenital hypogonadism and the effect of testosterone replacement therapy: A retrospective study
Introduction: Patients with hypogonadism are at increased risk for cardiovascular diseases. Mean platelet volume (MPV), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) are hematological indices that are surrogate markers of adverse cardiovascular outcomes. This study investigated the platelet count, MPV levels, PLR, and NLR in patients with congenital hypogonadotrophic hypogonadism (CHH) and also studied the effect of testosterone replacement therapy (TRT) on these parameters. Methods: A total of 67 young male patients with CHH (mean age: 21.5±2.0 years) and 68 healthy control subjects (mean age: 21.9±1.3 years) were enrolled in the study. The demographic parameters, homeostatic model assessment-insulin resistance (HOMA-IR), platelet count, MPV, PLR, and NLR were measured in patients with CHH and healthy controls before and after TRT. Results: The patients had higher WC (P=0.04), triglycerides (P=0.02), insulin (PPP=0.001), MPV (P=0.004), and PLR (P=0.003) levels and lower FSH, LH, and total testosterone (PPP=0.001, PP=0.03, respectively) and decreased HDL-C levels (Pr=−0.23, P=0.009), MPV (r=−0.0.22, P=0.013), and PLR. (r=−0.0.22, P=0.014). Conclusion: The present study showed that platelet activation may play a pivotal role in the pathogenesis of cardiometabolic risk of patients with hypogonadism. Moreover, the short time TRT in treatment naïve young patients with CHH did not have any effect on the platelet count and size.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Hematological indices in congenital hypogonadism and the effect of testosterone replacement therapy: A retrospective study
Introduction: Patients with hypogonadism are at increased risk for cardiovascular diseases. Mean platelet volume (MPV), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) are hematological indices that are surrogate markers of adverse cardiovascular outcomes. This study investigated the platelet count, MPV levels, PLR, and NLR in patients with congenital hypogonadotrophic hypogonadism (CHH) and also studied the effect of testosterone replacement therapy (TRT) on these parameters. Methods: A total of 67 young male patients with CHH (mean age: 21.5±2.0 years) and 68 healthy control subjects (mean age: 21.9±1.3 years) were enrolled in the study. The demographic parameters, homeostatic model assessment-insulin resistance (HOMA-IR), platelet count, MPV, PLR, and NLR were measured in patients with CHH and healthy controls before and after TRT. Results: The patients had higher WC (P=0.04), triglycerides (P=0.02), insulin (PPP=0.001), MPV (P=0.004), and PLR (P=0.003) levels and lower FSH, LH, and total testosterone (PPP=0.001, PP=0.03, respectively) and decreased HDL-C levels (Pr=−0.23, P=0.009), MPV (r=−0.0.22, P=0.013), and PLR. (r=−0.0.22, P=0.014). Conclusion: The present study showed that platelet activation may play a pivotal role in the pathogenesis of cardiometabolic risk of patients with hypogonadism. Moreover, the short time TRT in treatment naïve young patients with CHH did not have any effect on the platelet count and size.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Does follicle stimulating hormone effect adiposity in patients with hypergonadotrophic hypogonadism: a retrospective study
Introduction: Recent studies showed that post-menopausal osteoporosis and weight gain starts at the perimenopause stage, a period characterized by relatively stable estrogen and rising FSH levels. FSH is found to be associated with adiposity in women, which is also a great risk factor for type 2 DM. There is also a sharp increase in visceral adiposity during this life stage, which coincides with the emergence of disrupted energy balance and reduced physical activity. There is consistent evidence from basic and preclinical research that the disruption of estradiol signaling, accelerates fat accumulation. The excess fat seems to accumulate disproportionately in the abdominal region and leads to insulin resistance and dyslipidemia. We therefore decided to investigate the FSH – BMI and waist circumference relation in a small group of male patient with hyper gonadotrophic hypogonadism, who have similar laboratuary values of perimenopausal women. Methods: A total of 230 young male patients with newly diagnosed hyper gonadotrophic hypogonadism (mean age: 21.16±1.79 years) were analyzed retrospectively. 77 of the patients had a diagnose of Klinefelter’s syndrome, the rest didn’t have any genetic testing. Only the measurements at the time of diagnosis (untreated) were taken. FSH, LH, total and free testosterone, estradiol were analyzed for possible correlation with BMI and waist circumference. Results: The mean values of FSH, LH and total testosterone were all compatible with the diagnosis of hypergonadothrophic hypogonadism (Table 1). Only a slight negative correlation was found between LH and BMI. When we limited the analysis to the patients with documented diagnosis of Klinefelter’s syndrome the results were similar. Table 1 The demographic and metabolic parameters of the patients with hypergonadotrophic hypogonadism Patients (n=230) Age (yr) 21.16 (±1.79) Diag. of KS (n,%) .77 (33.5%) BMI (kg/m2) 22.35 (±4.03) AC (cm) 60.06 (±35.61) WC (cm) 71.02 (±39.51) Total-C (mg/dl) 163.46 (±30.42) FSH (mIU/ml) 347.64 (±33.66) LH (mIU/ml) 27.21 (±14.85) T.Testosterone (ng/dl) 0.93 (±0.93) F.Testosterone (μU/ml) 8.31 (±13.56) Estradiol (pg/mL) 22.48 (±18.67) Conclusion: We didn’t find any significant correlation between FSH and abdominal circumference, waist circumference or BMI. The younger age and low BMI values of our study population may play role on these results. The lack of body fat distribution analysis, either by bio-impedance or radiologic imaging techniques was also a limitation of our study.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Does follicle stimulating hormone effect adiposity in patients with hypergonadotrophic hypogonadism: a retrospective study
Introduction: Recent studies showed that post-menopausal osteoporosis and weight gain starts at the perimenopause stage, a period characterized by relatively stable estrogen and rising FSH levels. FSH is found to be associated with adiposity in women, which is also a great risk factor for type 2 DM. There is also a sharp increase in visceral adiposity during this life stage, which coincides with the emergence of disrupted energy balance and reduced physical activity. There is consistent evidence from basic and preclinical research that the disruption of estradiol signaling, accelerates fat accumulation. The excess fat seems to accumulate disproportionately in the abdominal region and leads to insulin resistance and dyslipidemia. We therefore decided to investigate the FSH – BMI and waist circumference relation in a small group of male patient with hyper gonadotrophic hypogonadism, who have similar laboratuary values of perimenopausal women. Methods: A total of 230 young male patients with newly diagnosed hyper gonadotrophic hypogonadism (mean age: 21.16±1.79 years) were analyzed retrospectively. 77 of the patients had a diagnose of Klinefelter’s syndrome, the rest didn’t have any genetic testing. Only the measurements at the time of diagnosis (untreated) were taken. FSH, LH, total and free testosterone, estradiol were analyzed for possible correlation with BMI and waist circumference. Results: The mean values of FSH, LH and total testosterone were all compatible with the diagnosis of hypergonadothrophic hypogonadism (Table 1). Only a slight negative correlation was found between LH and BMI. When we limited the analysis to the patients with documented diagnosis of Klinefelter’s syndrome the results were similar. Table 1 The demographic and metabolic parameters of the patients with hypergonadotrophic hypogonadism Patients (n=230) Age (yr) 21.16 (±1.79) Diag. of KS (n,%) .77 (33.5%) BMI (kg/m2) 22.35 (±4.03) AC (cm) 60.06 (±35.61) WC (cm) 71.02 (±39.51) Total-C (mg/dl) 163.46 (±30.42) FSH (mIU/ml) 347.64 (±33.66) LH (mIU/ml) 27.21 (±14.85) T.Testosterone (ng/dl) 0.93 (±0.93) F.Testosterone (μU/ml) 8.31 (±13.56) Estradiol (pg/mL) 22.48 (±18.67) Conclusion: We didn’t find any significant correlation between FSH and abdominal circumference, waist circumference or BMI. The younger age and low BMI values of our study population may play role on these results. The lack of body fat distribution analysis, either by bio-impedance or radiologic imaging techniques was also a limitation of our study.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Depression screening in adults with diabetes
Introduction: Elevated depressive symptoms and depressive disorders affect one in four patients with type 1 or type 2 diabetes (1). Thus, routine screening for depressive symptoms is indicated in this high-risk population. Current guidelines all recommend screening for depression in diabetic population(2). The Patient Health Questionnaire-9 (PHQ-9) is a valid screening tool for depression in individuals with diabetes (3). There is no specific data about the prevalence of depressive disorders diabetic population of Turkey. Therefore, we planned this study to investigate depressive disorder incidence in a small group of diabetic patient population. Methods: The demographic and laboratory parameters including glycated hemoglobin (HbA1c), lipid levels and body-mass indexes (BMI) were measured and PHQ-9 questionnaire was applied to all the diabetic patients admitted our endocrinology department and accepted to participate in the study. We used a cut-off point of 10 and above as high risk for depression in PHQ-9 questionnaire. Results: A total of 552 patients with diabetes (mean age 58.548±12.13) were enrolled in the study. Based on the predefined PHQ-9 cut-off value, 87 (16%) participants had depressive disorders. The patients with depressive disorders had worse HbA1c (7.91±2.05 vs. 8.52±2.44 in depression negative and positive groups, respectively; P=0.012), BMI (31.54±5.72 vs. 34.17±7.96 in depression negative and positive groups, respectively; P=0.005). Although statistically unimportant, LDL-C, non-HDL-C and FBG levels were also higher in the depressive disorder positive group. Patients of whom HbA1c was above target (uncontrolled diabetes) had higher PHQ-9 scores and there was a positive correlation detected between PHQ-9 score and HbA1c values (r=0.108, P=0.011). Conclusion: Depressive disorders prevalence is higher than expected in diabetic population. As recommended by guidelines every diabetic patient should be screened for depressive disorders periodically. PHQ-9 questionnaire is a practical and useful material for screening depressive disorders in diabetic patients.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Depression screening in adults with diabetes
Introduction: Elevated depressive symptoms and depressive disorders affect one in four patients with type 1 or type 2 diabetes (1). Thus, routine screening for depressive symptoms is indicated in this high-risk population. Current guidelines all recommend screening for depression in diabetic population(2). The Patient Health Questionnaire-9 (PHQ-9) is a valid screening tool for depression in individuals with diabetes (3). There is no specific data about the prevalence of depressive disorders diabetic population of Turkey. Therefore, we planned this study to investigate depressive disorder incidence in a small group of diabetic patient population. Methods: The demographic and laboratory parameters including glycated hemoglobin (HbA1c), lipid levels and body-mass indexes (BMI) were measured and PHQ-9 questionnaire was applied to all the diabetic patients admitted our endocrinology department and accepted to participate in the study. We used a cut-off point of 10 and above as high risk for depression in PHQ-9 questionnaire. Results: A total of 552 patients with diabetes (mean age 58.548±12.13) were enrolled in the study. Based on the predefined PHQ-9 cut-off value, 87 (16%) participants had depressive disorders. The patients with depressive disorders had worse HbA1c (7.91±2.05 vs. 8.52±2.44 in depression negative and positive groups, respectively; P=0.012), BMI (31.54±5.72 vs. 34.17±7.96 in depression negative and positive groups, respectively; P=0.005). Although statistically unimportant, LDL-C, non-HDL-C and FBG levels were also higher in the depressive disorder positive group. Patients of whom HbA1c was above target (uncontrolled diabetes) had higher PHQ-9 scores and there was a positive correlation detected between PHQ-9 score and HbA1c values (r=0.108, P=0.011). Conclusion: Depressive disorders prevalence is higher than expected in diabetic population. As recommended by guidelines every diabetic patient should be screened for depressive disorders periodically. PHQ-9 questionnaire is a practical and useful material for screening depressive disorders in diabetic patients.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Triglyceride-Glucose index levels in patients with congenital hypogonadism
Introduction: It is well known that patients with hypogonadism are at increased risk for insulin resistance and cardiovascular diseases. In many studies homeostatic model assessment-insulin resistance (HOMA-IR) formulation is used for the evaluation of insulin resistance. Recently, a simple and inexpensive approach to evaluate for insulin resistance has been developed, the Triglyceride – Glucose (TyG) index. This particular index is based on measuring the levels of fasting triglycerides and glucose. This study investigated the TyG index as a useful surrogate marker of insulin resistance among patients with congenital hypo gonadotrophic hypogonadism (CHH). Methods: A total of 154 young male patients with CHH (mean age: 21.54±1.95 years) and 115 healthy control subjects (mean age: 22.81±1.45 years) were enrolled in the study. The demographic and laboratory parameters, plasma ADMA, hsCRP, HOMA-IR levels and TyG index were measured in healthy controls and patients with CHH, before and after TRT. Results: The patients had higher waist circumference (WC, P=0.011), systolic blood pressure (SBP, P=0.011), triglycerides (Tg, PPPPP=0.004) levels and lower follicle stimulating hormone (FSH), luteinizing hormone (LH), and total testosterone (PPPP=0.002), Tg (PP=0.012), HOMA-IR (PPPPr=0.15, P=0.03), WC (r=0.25, Pr=−0.21, P=0.001), LDL-C (r=0.15, P=0.032) and ADMA (r=0.17, P=0.03) levels. Conclusion: The results of the present study show that patients with CHH have elevated TyG index which is an easily calculated and inexpensive parameter that can indicate insulin resistance. TyG index is further increased after TRT and also related to surrogate marker of endothelial dysfunction. Prospective follow-up studies are warranted to clarify the role of TyG index in predicting cardiometabolic risk in patients with hypogonadism.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Triglyceride-Glucose index levels in patients with congenital hypogonadism
Introduction: It is well known that patients with hypogonadism are at increased risk for insulin resistance and cardiovascular diseases. In many studies homeostatic model assessment-insulin resistance (HOMA-IR) formulation is used for the evaluation of insulin resistance. Recently, a simple and inexpensive approach to evaluate for insulin resistance has been developed, the Triglyceride – Glucose (TyG) index. This particular index is based on measuring the levels of fasting triglycerides and glucose. This study investigated the TyG index as a useful surrogate marker of insulin resistance among patients with congenital hypo gonadotrophic hypogonadism (CHH). Methods: A total of 154 young male patients with CHH (mean age: 21.54±1.95 years) and 115 healthy control subjects (mean age: 22.81±1.45 years) were enrolled in the study. The demographic and laboratory parameters, plasma ADMA, hsCRP, HOMA-IR levels and TyG index were measured in healthy controls and patients with CHH, before and after TRT. Results: The patients had higher waist circumference (WC, P=0.011), systolic blood pressure (SBP, P=0.011), triglycerides (Tg, PPPPP=0.004) levels and lower follicle stimulating hormone (FSH), luteinizing hormone (LH), and total testosterone (PPPP=0.002), Tg (PP=0.012), HOMA-IR (PPPPr=0.15, P=0.03), WC (r=0.25, Pr=−0.21, P=0.001), LDL-C (r=0.15, P=0.032) and ADMA (r=0.17, P=0.03) levels. Conclusion: The results of the present study show that patients with CHH have elevated TyG index which is an easily calculated and inexpensive parameter that can indicate insulin resistance. TyG index is further increased after TRT and also related to surrogate marker of endothelial dysfunction. Prospective follow-up studies are warranted to clarify the role of TyG index in predicting cardiometabolic risk in patients with hypogonadism.
- Open Access
- 1 June 2017
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 61 (3) , 282-287
Visceral adiposity index and triglyceride/high-density lipoprotein cholesterol ratio in hypogonadism
Key words: Hypogonadism; cardiometabolic risk; visceral adiposity index; triglyceride/high-density lipoprotein cholesterol ratio
- 1 June 2017
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 61 (3) , 282-287
Open AccessVisceral adiposity index and triglyceride/high-density lipoprotein cholesterol ratio in hypogonadism
Key words: Hypogonadism; cardiometabolic risk; visceral adiposity index; triglyceride/high-density lipoprotein cholesterol ratio